{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T08:22:30Z","timestamp":1781770950104,"version":"3.54.5"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T00:00:00Z","timestamp":1649635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T00:00:00Z","timestamp":1649635200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006259","name":"Teva Pharmaceuticals","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The efficacy and tolerability of fremanezumab, a fully humanized monoclonal antibody (IgG2\u0394a) that selectively targets calcitonin gene-related peptide (CGRP) and is approved for the preventive treatment of migraine in adults, have been demonstrated in randomized, double-blind, placebo-controlled trials. Real-world data can further support those clinical trial data and demonstrate the full clinical benefits of fremanezumab. This chart review assessed the effectiveness of fremanezumab for improving clinical outcomes in adult patients with migraine treated according to real-world clinical practice.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This retrospective, panel-based, online physician chart review study used electronic case report forms with US physicians. Patient inclusion criteria were a physician diagnosis of migraine, fremanezumab treatment initiation at\u2009\u2265\u200918\u00a0years of age after US Food and Drug Administration approval,\u2009\u2265\u20091 dose of fremanezumab treatment, and\u2009\u2265\u20092 assessments of monthly migraine days (MMD; 1 within 30\u00a0days before treatment initiation and\u2009\u2265\u20091 after initiation). Changes from baseline in MMD, monthly headache days (MHD), and Migraine Disability Assessment (MIDAS) and 6-item Headache Impact Test (HIT-6) scores were assessed over 6\u00a0months. These endpoints were evaluated in the overall population and subgroups divided by dosing schedule and number of prior migraine preventive treatment failures.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>This study included data from 421 clinicians and 1003 patients. Mean age at fremanezumab initiation was 39.7\u00a0years, and most patients were female (75.8%). In the overall population, mean baseline MMD and MHD were 12.7 and 14.0, respectively. Mean (percent) reductions from baseline in MMD and MHD, respectively, were\u2009\u2212\u20094.6 (36.2%) and\u2009\u2212\u20094.7 (33.6%) at Month 1,\u2009\u2212\u20096.7 (52.8%) and\u2009\u2212\u20096.8 (48.6%) at Month 3, and\u2009\u2212\u20099.2 (72.4%) and\u2009\u2212\u20099.8 (70.0%) at Month 6. Mean (percent) reductions from baseline in MIDAS and HIT-6 scores also increased over the 6-month study period, from\u2009\u2212\u20096.2 (21.6%) and\u2009\u2212\u20098.4 (14.0%) at Month 1 to\u2009\u2212\u200918.1 (63.1%) and\u2009\u2212\u200916.2 (27.0%) at Month 6, respectively. Improvements in these outcomes over 6\u00a0months were observed across all evaluated subgroups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This real-world study demonstrated effectiveness of fremanezumab treatment for up to 6\u00a0months, irrespective of dosing regimen or number of prior migraine preventive treatment failures, reflecting ongoing, clinically meaningful improvements in patient outcomes.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s10194-022-01411-1","type":"journal-article","created":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T12:04:12Z","timestamp":1649678652000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Real-world effectiveness of fremanezumab in migraine patients initiating treatment in the United States: results from a retrospective chart study"],"prefix":"10.1186","volume":"23","author":[{"given":"Maurice T.","family":"Driessen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua M.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Patterson-Lomba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen F.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Seminerio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Carr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todor I.","family":"Totev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rochelle","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Yim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajeev","family":"Ayyagari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,11]]},"reference":[{"key":"1411_CR1","first-page":"165","volume":"78","author":"VL Feigin","year":"2020","unstructured":"Feigin VL, Vos T, Alahdab F, Amit AML, Barnighausen TW, Beghi E et al (2020) Burden of neurological disorders across the US from 1990\u20132017: a global burden of disease study. JAMA Neurol 78:165\u2013176","journal-title":"JAMA Neurol"},{"key":"1411_CR2","first-page":"1334","volume":"26","author":"DC Buse","year":"2020","unstructured":"Buse DC, Yugrakh MS, Lee LK, Bell J, Cohen JM, Lipton RB (2020) Burden of illness among people with migraine and \u2265 4 monthly headache days while using acute and\/or preventive prescription medications for migraine. J Manag Care Spec Pharm 26:1334\u20131343","journal-title":"J Manag Care Spec Pharm"},{"key":"1411_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2016.02.013.2016;91:596-611","author":"DC Buse","year":"2016","unstructured":"Buse DC, Scher AI, Dodick DW, Reed ML, Fanning KM, Manack Adams A et al (2016) Impact of migraine on the family: perspectives of people with migraine and their spouse\/domestic partner in the CaMEO Study. Mayo Clin Proc. https:\/\/doi.org\/10.1016\/j.mayocp.2016.02.013.2016;91:596-611","journal-title":"Mayo Clin Proc"},{"key":"1411_CR4","first-page":"1344","volume":"26","author":"RB Lipton","year":"2020","unstructured":"Lipton RB, Lee L, Saikali NP, Bell J, Cohen JM (2020) Effect of headache-free days on disability, productivity, quality of life, and costs among individuals with migraine. J Manag Care Spec Pharm 26:1344\u20131352","journal-title":"J Manag Care Spec Pharm"},{"key":"1411_CR5","unstructured":"American Academy of Neurology. Headache quality management set. 2014. https:\/\/www.aan.com\/siteassets\/home-page\/policy-and-guidelines\/quality\/quality-measures\/14headachemeasureset_pg.pdf. Accessed 23 Nov 2021."},{"key":"1411_CR6","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1212\/WNL.0b013e3182535d20","volume":"78","author":"SD Silberstein","year":"2012","unstructured":"Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E, Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society (2012) Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the quality standards subcommittee of the American academy of neurology and the American headache society. Neurology 78:1337\u20131345","journal-title":"Neurology"},{"key":"1411_CR7","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1177\/0333102416678382","volume":"37","author":"Z Hepp","year":"2017","unstructured":"Hepp Z, Dodick DW, Varon SF, Chia J, Matthew N, Gillard P et al (2017) Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: a retrospective claims analysis. Cephalalgia 37:470\u2013485","journal-title":"Cephalalgia"},{"key":"1411_CR8","doi-asserted-by":"publisher","first-page":"22","DOI":"10.18553\/jmcp.2014.20.1.22","volume":"20","author":"Z Hepp","year":"2014","unstructured":"Hepp Z, Bloudek LM, Varon SF (2014) Systematic review of migraine prophylaxis adherence and persistence. J Manag Care Pharm 20:22\u201333","journal-title":"J Manag Care Pharm"},{"key":"1411_CR9","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1111\/head.12055","volume":"53","author":"AM Blumenfeld","year":"2013","unstructured":"Blumenfeld AM, Bloudek LM, Becker WJ, Buse DC, Varon SF, Maglinte GA et al (2013) Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the Second International Burden of Migraine Study (IBMS-II). Headache 53:644\u2013655","journal-title":"Headache"},{"key":"1411_CR10","unstructured":"AJOVY (fremanezumab-vfrm) [prescribing information]. North Wales: Teva Pharmaceuticals USA, Inc. Revised 2021.\u00a0https:\/\/www.ajovyhcp.com\/globalassets\/ajovy\/ajovy-pi.pdf. Accessed 23 Nov 2021."},{"key":"1411_CR11","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1001\/jama.2018.4853","volume":"319","author":"DW Dodick","year":"2018","unstructured":"Dodick DW, Silberstein SD, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T et al (2018) Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. JAMA 319:1999\u20132008","journal-title":"JAMA"},{"key":"1411_CR12","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/S0140-6736(19)31946-4","volume":"394","author":"MD Ferrari","year":"2019","unstructured":"Ferrari MD, Diener HC, Ning X, Galic M, Cohen JM, Yang R et al (2019) Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Lancet 394:1030\u20131040","journal-title":"Lancet"},{"key":"1411_CR13","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa1709038","volume":"377","author":"SD Silberstein","year":"2017","unstructured":"Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T et al (2017) Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med 377:2113\u20132122","journal-title":"N Engl J Med"},{"key":"1411_CR14","doi-asserted-by":"publisher","first-page":"e2487","DOI":"10.1212\/WNL.0000000000010600","volume":"95","author":"PJ Goadsby","year":"2020","unstructured":"Goadsby PJ, Silberstein SD, Yeung PP, Cohen JM, Ning X, Yang R et al (2020) Long-term safety, tolerability, and efficacy of fremanezumab in migraine: a randomized study. Neurology 95:e2487\u2013e2499","journal-title":"Neurology"},{"key":"1411_CR15","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s10194-020-01127-0","volume":"21","author":"G Lambru","year":"2020","unstructured":"Lambru G, Hill B, Murphy M, Tylova I, Andreou AP (2020) A prospective real-world analysis of erenumab in refractory chronic migraine. J Headache Pain 21:61","journal-title":"J Headache Pain"},{"key":"1411_CR16","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1111\/head.13951","volume":"60","author":"J Robblee","year":"2020","unstructured":"Robblee J, Devick KL, Mendez N, Potter J, Slonaker J, Starling AJ (2020) Real-world patient experience with erenumab for the preventive treatment of migraine. Headache 60:2014\u20132025","journal-title":"Headache"},{"key":"1411_CR17","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1177\/0333102420946725","volume":"40","author":"S Kanaan","year":"2020","unstructured":"Kanaan S, Hettie G, Loder E, Burch R (2020) Real-world effectiveness and tolerability of erenumab: a retrospective cohort study. Cephalalgia 40:1511\u20131522","journal-title":"Cephalalgia"},{"key":"1411_CR18","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1111\/head.13956","volume":"60","author":"A Alex","year":"2020","unstructured":"Alex A, Vaughn C, Rayhill M (2020) Safety and tolerability of 3 CGRP monoclonal antibodies in practice: a retrospective cohort study. Headache 60:2454\u20132462","journal-title":"Headache"},{"key":"1411_CR19","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s10194-020-01102-9","volume":"21","author":"R Ornello","year":"2020","unstructured":"Ornello R, Casalena A, Frattale I, Gabriele A, Affaitati G, Giamberardino MA et al (2020) Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy. J Headache Pain 21:32","journal-title":"J Headache Pain"},{"key":"1411_CR20","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1177\/0333102421989247","volume":"41","author":"HC Diener","year":"2021","unstructured":"Diener HC, Ashina M, Durand-Zaleski I, Kurth T, Lanteri-Minet M, Lipton RB et al (2021) Health technology assessment for the acute and preventive treatment of migraine: a position statement of the International Headache Society. Cephalalgia 41:279\u2013293","journal-title":"Cephalalgia"},{"key":"1411_CR21","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1177\/0333102410379890","volume":"31","author":"M Yang","year":"2011","unstructured":"Yang M, Rendas-Baum R, Varon SF, Kosinski M (2011) Validation of the Headache Impact Test (HIT-6) across episodic and chronic migraine. Cephalalgia 31:357\u2013367","journal-title":"Cephalalgia"},{"key":"1411_CR22","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1212\/WNL.56.suppl_1.S20","volume":"56","author":"WF Stewart","year":"2001","unstructured":"Stewart WF, Lipton RB, Dowson AJ, Sawyer J (2001) Development and testing of the Migraine Disability Assessment (MIDAS) Questionnaire to assess headache-related disability. Neurology 56:S20\u2013S28","journal-title":"Neurology"},{"key":"1411_CR23","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1111\/head.13946","volume":"60","author":"CR Houts","year":"2020","unstructured":"Houts CR, Wirth RJ, McGinley JS, Cady R, Lipton RB (2020) Determining thresholds for meaningful change for the Headache Impact Test (HIT-6) total and item-specific scores in chronic migraine. Headache 60:2003\u20132013","journal-title":"Headache"},{"key":"1411_CR24","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1177\/0333102412449933","volume":"32","author":"RF Castien","year":"2012","unstructured":"Castien RF, Blankenstein AH, Windt DA, Dekker J (2012) Minimal clinically important change on the Headache Impact Test-6 questionnaire in patients with chronic tension-type headache. Cephalalgia 32:710\u2013714","journal-title":"Cephalalgia"},{"key":"1411_CR25","doi-asserted-by":"publisher","first-page":"965","DOI":"10.2217\/fon-2020-0951","volume":"17","author":"B Nazha","year":"2021","unstructured":"Nazha B, Yang JC, Owonikoko TK (2021) Benefits and limitations of real-world evidence: lessons from EGFR mutation-positive non-small-cell lung cancer. Future Oncol 17:965\u2013977","journal-title":"Future Oncol"},{"key":"1411_CR26","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1177\/03331024211008401","volume":"41","author":"L Pazdera","year":"2021","unstructured":"Pazdera L, Cohen JM, Ning X, Campos VR, Yang R, Pozo-Rosich P (2021) Fremanezumab for the preventive treatment of migraine: subgroup analysis by number of prior preventive treatments with inadequate response. Cephalalgia 41:1075\u20131088","journal-title":"Cephalalgia"},{"key":"1411_CR27","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1177\/0333102418788347","volume":"38","author":"M Ashina","year":"2018","unstructured":"Ashina M, Tepper S, Brandes JL, Reuter U, Boudreau G, Dolezil D et al (2018) Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: a subgroup analysis of a randomized, double-blind, placebo-controlled study. Cephalalgia 38:1611\u20131621","journal-title":"Cephalalgia"},{"key":"1411_CR28","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1177\/0333102420912726","volume":"40","author":"SJ Tepper","year":"2020","unstructured":"Tepper SJ, Ashina M, Reuter U, Brandes JL, Dolezil D, Silberstein SD et al (2020) Long-term safety and efficacy of erenumab in patients with chronic migraine: results from a 52-week, open-label extension study. Cephalalgia 40:543\u2013553","journal-title":"Cephalalgia"},{"key":"1411_CR29","doi-asserted-by":"publisher","first-page":"3789","DOI":"10.1007\/s00415-021-10523-8","volume":"268","author":"M Torres-Ferrus","year":"2021","unstructured":"Torres-Ferrus M, Gallardo VJ, Alpuente A, Caronna E, Gine-Cipres E, Pozo-Rosich P (2021) The impact of anti-CGRP monoclonal antibodies in resistant migraine patients: a real-world evidence observational study. J Neurol 268:3789\u20133798","journal-title":"J Neurol"},{"key":"1411_CR30","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s10072-020-04669-y","volume":"41","author":"F Vernieri","year":"2020","unstructured":"Vernieri F, Altamura C, Aurilia C, Brunelli N, Egeo G, Fofi L et al (2020) Effectiveness, safety, and tolerability of galcanezumab in a real-life setting in patients with migraine in Italy (the GARLIT study). Neurol Sci 41:487\u2013488","journal-title":"Neurol Sci"},{"key":"1411_CR31","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s40120-021-00245-4","volume":"10","author":"E Faust","year":"2021","unstructured":"Faust E, Pivneva I, Yang K, Betts KA, Ahmed Z, Joshi S et al (2021) Real-world treatment profiles, clinical outcomes, and healthcare resource utilization of patients with migraine prescribed erenumab: a multicenter chart-review study of US headache centers. Neurol Ther 10:293\u2013306","journal-title":"Neurol Ther"},{"key":"1411_CR32","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1111\/head.13314","volume":"58","author":"DC Buse","year":"2018","unstructured":"Buse DC, Gillard P, Arctander K, Kuang AW, Lipton RB (2018) Assessing physician-patient dialogues about chronic migraine during routine office visits. Headache 58:993\u20131006","journal-title":"Headache"},{"key":"1411_CR33","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1177\/0333102414547138","volume":"35","author":"Z Hepp","year":"2015","unstructured":"Hepp Z, Dodick DW, Varon SF, Gillard P, Hansen RN, Devine EB (2015) Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia 35:478\u2013488","journal-title":"Cephalalgia"},{"key":"1411_CR34","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1111\/head.13157","volume":"57","author":"JM Woolley","year":"2017","unstructured":"Woolley JM, Bonafede MM, Maiese BA, Lenz RA (2017) Migraine prophylaxis and acute treatment patterns among commercially insured patients in the United States. Headache 57:1399\u20131408","journal-title":"Headache"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-022-01411-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-022-01411-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-022-01411-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T12:04:19Z","timestamp":1649678659000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-022-01411-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,11]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1411"],"URL":"https:\/\/doi.org\/10.1186\/s10194-022-01411-1","relation":{},"ISSN":["1129-2369","1129-2377"],"issn-type":[{"value":"1129-2369","type":"print"},{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,11]]},"assertion":[{"value":"7 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. All analyses were conducted using de-identified data and did not meet the definition of human subject research, so Institutional Review Board approval and patient informed consent were not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"M.T.D., S.T., M.S., and K.C. are employees of Teva Pharmaceuticals. J.M.C. is a former employee of Teva Pharmaceuticals. O.P.L., T.I.T., R.S., E.Y., F.M., and R.A. are employees of Analysis Group, which performed these analysis funded by Teva Pharmaceuticals.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"47"}}